Aastrom to Present 12-Month Data From the IMPACT-DCM Phase 2 Clinical Trial for Ixmyelocel-T in Treatment of Dilated Cardiomy...
September 14 2011 - 8:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, will present
safety and efficacy data from a 12-month study of patients with
dilated cardiomyopathy treated with the company's cell therapy
product, ixmyelocel-T. Results will be presented on September 19,
2011, in a poster presentation at the 15th Annual Heart Failure
Society of America Scientific Meeting in Boston, Massachusetts.
Amit N. Patel, MD, MS, associate professor of surgery at the
University of Utah School of Medicine and national principal
investigator in Aastrom's U.S. Phase 2 IMPACT-DCM clinical trial,
will present a poster entitled: "Safety and Efficacy of
Ixmyelocel-T, an Expanded Patient-Specific Mixed Cell Product, in
Dilated Cardiomyopathy (IMPACT-DCM)." Dr. Patel's presentation will
take place from 5:45 P.M. to 6:45 P.M. (EDT), and the poster will
be on display from 9:30 A.M. to 7:00 P.M. (EDT).
"We are very pleased that Dr. Patel will be available to review
the findings from the 12-month study of patients treated with
ixmyelocel-T using surgical administration of our product. We also
look forward to announcing data from the 6-month study of patients
in our catheter-DCM study in the coming weeks," said Tim M.
Mayleben, president and chief executive officer at Aastrom.
About Aastrom Biosciences
Aastrom Biosciences is developing patient-specific, expanded
multicellular therapies for use in the treatment of severe, chronic
cardiovascular diseases. The company's proprietary cell-processing
technology enables the manufacture of ixmyelocel-T, a
patient-specific multicellular therapy expanded from a patient's
own bone marrow and delivered directly to damaged tissues. Aastrom
has advanced ixmyelocel-T into late-stage clinical development,
including a planned Phase 3 clinical program to study patients with
critical limb ischemia and two Phase 2 clinical trials in patients
with dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Bill Berry
Berry & Company
bberry@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024